What's Happening?
SpinaFX Medical has received an Investigational Device Exemption (IDE) from the FDA for its Triojection® treatment, a minimally invasive, image-guided therapy for lumbar disc disorders. The IDE approval allows SpinaFX to initiate a pivotal U.S. clinical
trial comparing intradiscal ozone/oxygen injection plus nerve root block to nerve root block alone in patients with contained herniated lumbar discs. The trial aims to enroll 300 patients across 30 U.S. sites, evaluating the treatment's safety, effectiveness, and economic impact.
Why It's Important?
The FDA's IDE approval for Triojection represents a significant milestone for SpinaFX Medical, enabling the company to conduct a pivotal trial in the U.S. This trial could provide critical data on the safety and efficacy of Triojection, potentially offering a new minimally invasive treatment option for patients with lumbar disc disorders. If successful, Triojection could fill a therapeutic gap between conservative care and surgery, improving patient outcomes and reducing healthcare costs associated with spinal disorders.
